STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments
Source ↗
👁 2
💬 0
Medicines for brittle bones and breakages are grabbing the attention of the pharma industry, which has been incentivized by a long-awaited regulatory change. 
Osteoporosis, a condition affecting older adults that causes bones to become thin and fragile, used to be a top priority for pharmaceutical companies. Eli Lilly, Merck, Novartis, and GSK each had their own treatment designed to stop bones from weakening. But the cumbersome requirements for taking the drugs, as well as a series of s
Osteoporosis, a condition affecting older adults that causes bones to become thin and fragile, used to be a top priority for pharmaceutical companies. Eli Lilly, Merck, Novartis, and GSK each had their own treatment designed to stop bones from weakening. But the cumbersome requirements for taking the drugs, as well as a series of s
Comments (0)